المؤلفون: Pieter Willem Kamphuisen, Ranjeeta Mallick, Marc Carrier, Phill S Wells, Nick van Es, Frits I. Mulder, Saskia Middeldorp, Floris T. M. Bosch

المساهمون: Graduate School, Vascular Medicine, ACS - Pulmonary hypertension & thrombosis, Amsterdam Reproduction & Development (AR&D), ACS - Atherosclerosis & ischemic syndromes

المصدر: Journal of Thrombosis and Haemostasis, 20, 138-144
Journal of Thrombosis and Haemostasis, 20, 1, pp. 138-144
Journal of thrombosis and haemostasis, 20(1), 138-144. Wiley-Blackwell

مصطلحات موضوعية: medicine.medical_specialty, Growth Differentiation Factor 15, venous thromboembolism, Vascular damage Radboud Institute for Health Sciences [Radboudumc 16], neoplasms, Placebo, Internal medicine, Humans, Medicine, risk, business.industry, Anticoagulants, Cancer, biomarkers, Atrial fibrillation, Hematology, medicine.disease, embryonic structures, Biomarker (medicine), Apixaban, GDF15, hemorrhage, business, Risk assessment, Venous thromboembolism, medicine.drug

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97a08108025e4b86ac55dd05fd07d1a1
http://hdl.handle.net/2066/248717